華北製藥(600812.SH):氨苄西林鈉獲得化學原料藥上市申請批准通知書
格隆匯5月31日丨華北製藥(600812.SH)公佈,下屬全資子公司華北製藥集團先泰藥業有限公司收到國家藥品監督管理局核准簽發的氨苄西林鈉《化學原料藥上市申請批准通知書》,氨苄西林鈉為廣譜半合成青黴素。本品對溶血性鏈球菌、肺炎鏈球菌和不產青黴素酶葡萄球菌具較強抗菌作用。對草綠色鏈球菌亦有良好抗菌作用,對腸球菌屬和李斯德菌屬的作用優於青黴素。本品對白喉棒狀桿菌、炭疽芽孢桿菌、放線菌屬、流感嗜血桿菌、百日咳鮑特桿菌、奈瑟菌屬以及除脆弱擬桿菌外的厭氧菌均具抗菌活性,部分奇異變形桿菌、大腸埃希菌、沙門菌屬和志賀菌屬細菌對本品敏感。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.